QNCX Company Profile and Key Details

QNCX has shown sold momentum, gaining 15.93% over the past week and 83.87% over the past quarter, though year-to-date performance is up 2.09%. Short-term trend indicators are mixed aligned (SMA20 -32.85%, SMA50 -93.19%, SMA200 -92.44%). The stock’s 14-day RSI is 27.88 (weak momentum), while the ATR of 0.19 points to tighter daily ranges. The stock remains sitting in the mid-range of its 52-week band, trading -96.96% below its high and over 10.71% above its low. Average 10-day trading volume of 14.84 thousand shares is below the 3-month average of 29.23 thousand, indicating normal recent market interest.

Quince Therapeutics, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$0.20. This means the shares are trading below this model’s fair value.

Quince Therapeutics, Inc. has 1.02 million shares outstanding. The public float is 666.19 thousand shares, elevated short interest at 5.58% of float. This equals 56.63 thousand shares. The short ratio is 1.35 days. Institutional investors hold 14.23% of the float. Insiders own 0.32%. EPIQ Capital Group, LLC holds 2.86 million shares, Lamond David has 2.35 million shares and Thye Dirk has 843.94 thousand shares.

Quince Therapeutics, Inc. (NASDAQ:QNCX) closed at $29.55 USD, gaining $0.59 (2.04%) from the previous close of $28.96. The stock is currently mid-range between its 52-week high and low $15.10 and $910.00. With a market capitalization of about $8.23 million, Quince Therapeutics, Inc. is classified as a micro-cap and shows higher-than-market volatility (beta ~1.31). Key stats such as the average daily volume over the past year has been around 29.77 thousand shares, volume is running light vs its 52-week average. Headquartered in South San Francisco, CA, Quince Therapeutics, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Dirk Thye, the company employs approximately 38 people and listed since May 09, 2019. Quince Therapeutics, Inc. (QNCX) operates as a biopharmaceutical firm dedicated to developing targeted treatments for debilitating and rare diseases.

Quince Therapeutics, Inc. generated EPS of -$1.22 over the past year. Five-year average earnings growth is 7.53%. Wall Street analysts project EPS growth of 47.53% annually over the next five years. Analyst sentiment is bullish. Analyst rating data shows there are 3 Strong Buy ratings, 4 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $82.00 to $4.00. The high target offers 177.5% upside. The low target suggests -86.46% downside. The mean target is $15.43. This offers -47.78% upside. Quince Therapeutics, Inc. earnings surprise history is a mixed track record. The quarter that ended August 14, 2026, missed forecasts by -56.07%. The prior quarter beat by -2.62%. Over the last six quarters, Apple has recorded several small beats. These include 24.57% in November 12, 2025.

Quince Therapeutics, Inc. (NASDAQ:QNCX) shares are flat 2.09% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Quince Therapeutics, Inc. trading at a premium to the broader market with a P/E of -0.42. Analyst sentiment is bullish, with the majority of ratings in Outperform territory and a mean price target of $10.89, suggesting -63.15% downside. Our AI forecast model points to short-term weakness (-5.99% over two weeks), a medium-term fall (-100.0% over three months), and a longer-term gain (126.5% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that Quince Therapeutics, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -5.99%, with price expected at $27.78 by September 24, 2026, within a range of $25.81 to $29.79 3-Month Outlook: Projected fall of -100.0%, reaching $0.00 by December 09, 2026, with a range of $0.00 to $18.32. 1-Year Outlook: Projected gain of 126.5%, with price at $66.93 by September 10, 2027, within a range of $6.25 to $120.36.

Quince Therapeutics, Inc. trades at a P/E ratio of -0.42, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 1.62 suggesting the stock is closer to book value. The P/FCF stands at -0.17, also above market averages.